249 related articles for article (PubMed ID: 23549103)
1. Immune suppression in cynomolgus monkeys by XPro9523: an improved CTLA4-Ig fusion with enhanced binding to CD80, CD86 and neonatal Fc receptor FcRn.
Bernett MJ; Chu SY; Leung I; Moore GL; Lee SH; Pong E; Chen H; Phung S; Muchhal US; Horton HM; Lazar GA; Desjarlais JR; Szymkowski DE
MAbs; 2013; 5(3):384-96. PubMed ID: 23549103
[TBL] [Abstract][Full Text] [Related]
2. Immunosuppressive effect of ASP2408, a novel CD86-selective variant of CTLA4-Ig, in rats and cynomolgus monkeys.
Oshima S; Fujii Y; Karrer EE; Takamura F; Chapin SJ; Neighbors M; Viswanathan S; Devens BH; Higashi Y; Mizuhara H
Int Immunopharmacol; 2016 Nov; 40():310-317. PubMed ID: 27662596
[TBL] [Abstract][Full Text] [Related]
3. The Effect of ASP2409, a Novel CD86-Selective Variant of CTLA4-Ig, on Renal Allograft Rejection in Nonhuman Primates.
Oshima S; Karrer EE; Kawato Y; Maeda M; Fukahori H; Tsujimoto S; Hirose J; Nakamura K; Marui T; Takamura F; Noto T; Chapin SJ; Fujii Y; Neighbors M; Viswanathan S; Devens BH; Higashi Y
Transplantation; 2016 Dec; 100(12):2611-2620. PubMed ID: 27861289
[TBL] [Abstract][Full Text] [Related]
4. A CD80-Biased CTLA4-Ig Fusion Protein with Superior In Vivo Efficacy by Simultaneous Engineering of Affinity, Selectivity, Stability, and FcRn Binding.
Douthwaite J; Moisan J; Privezentzev C; Soskic B; Sabbah S; Cohen S; Collinson A; England E; Huntington C; Kemp B; Zhuang L; Hudak S; Rees DG; Goldberg D; Barton C; Chang L; Vainshtein I; Liang M; Iciek L; Ambery P; Peakman M; Vaughan TJ; Tree TI; Sansom DM; Bowen MA; Minter RR; Jermutus L
J Immunol; 2017 Jan; 198(1):528-537. PubMed ID: 27881707
[TBL] [Abstract][Full Text] [Related]
5. ASP2408 and ASP2409, novel CTLA4-Ig variants with CD86-selective ligand binding activity and improved immunosuppressive potency, created by directed evolution.
Oshima S; Karrer EE; Paidhungat MM; Neighbors M; Chapin SJ; Fan RA; Reed MA; Wu K; Wong C; Chen Y; Whitlow M; Anderson FA; Bam RA; Zhang Q; Larsen BR; Viswanathan S; Devens BH; Bass SH; Higashi Y
Protein Eng Des Sel; 2016 May; 29(5):159-67. PubMed ID: 26968452
[TBL] [Abstract][Full Text] [Related]
6. Affinity and cross-reactivity engineering of CTLA4-Ig to modulate T cell costimulation.
Xu Z; Juan V; Ivanov A; Ma Z; Polakoff D; Powers DB; Dubridge RB; Wilson K; Akamatsu Y
J Immunol; 2012 Nov; 189(9):4470-7. PubMed ID: 23018459
[TBL] [Abstract][Full Text] [Related]
7. ASP2409, A Next-Generation CTLA4-Ig, Versus Belatacept in Renal Allograft Survival in Cynomolgus Monkeys.
Song L; Ma A; Dun H; Hu Y; Fujii Y; Kinugasa F; Oshima S; Higashi Y; Daloze P; Chen H
Am J Transplant; 2017 Mar; 17(3):635-645. PubMed ID: 27598231
[TBL] [Abstract][Full Text] [Related]
8. Porcine CTLA4-Ig lacks a MYPPPY motif, binds inefficiently to human B7 and specifically suppresses human CD4+ T cell responses costimulated by pig but not human B7.
Vaughan AN; Malde P; Rogers NJ; Jackson IM; Lechler RI; Dorling A
J Immunol; 2000 Sep; 165(6):3175-81. PubMed ID: 10975832
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxic T lymphocyte-associated antigen-4-Ig (CTLA-4-Ig) suppresses Staphylococcus aureus-induced CD80, CD86, and pro-inflammatory cytokine expression in human B cells.
Liu PC; Ssu CT; Tsao YP; Liou TL; Tsai CY; Chou CT; Chen MH; Leu CM
Arthritis Res Ther; 2020 Mar; 22(1):64. PubMed ID: 32228715
[TBL] [Abstract][Full Text] [Related]
10. Differential requirement for CD80 and CD80/CD86-dependent costimulation in the lung immune response to an influenza virus infection.
Lumsden JM; Roberts JM; Harris NL; Peach RJ; Ronchese F
J Immunol; 2000 Jan; 164(1):79-85. PubMed ID: 10604996
[TBL] [Abstract][Full Text] [Related]
11. Abatacept modulates CD80 and CD86 expression and memory formation in human B-cells.
Lorenzetti R; Janowska I; Smulski CR; Frede N; Henneberger N; Walter L; Schleyer MT; Hüppe JM; Staniek J; Salzer U; Venhoff A; Troilo A; Voll RE; Venhoff N; Thiel J; Rizzi M
J Autoimmun; 2019 Jul; 101():145-152. PubMed ID: 31054942
[TBL] [Abstract][Full Text] [Related]
12. CTLA4-Ig interacts with cultured synovial macrophages from rheumatoid arthritis patients and downregulates cytokine production.
Cutolo M; Soldano S; Montagna P; Sulli A; Seriolo B; Villaggio B; Triolo P; Clerico P; Felli L; Brizzolara R
Arthritis Res Ther; 2009; 11(6):R176. PubMed ID: 19930661
[TBL] [Abstract][Full Text] [Related]
13. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties.
Larsen CP; Pearson TC; Adams AB; Tso P; Shirasugi N; Strobert E; Anderson D; Cowan S; Price K; Naemura J; Emswiler J; Greene J; Turk LA; Bajorath J; Townsend R; Hagerty D; Linsley PS; Peach RJ
Am J Transplant; 2005 Mar; 5(3):443-53. PubMed ID: 15707398
[TBL] [Abstract][Full Text] [Related]
14. CTLA4-Ig-Based Bifunctional Costimulation Inhibitor Blocks CD28 and ICOS Signaling to Prevent T Cell Priming and Effector Function.
Goenka R; Xu Z; Samayoa J; Banach D; Beam C; Bose S; Dooner G; Forsyth CM; Lu X; Medina L; Sadhukhan R; Sielaff B; Sousa S; Tao Q; Touw D; Wu F; Kingsbury GA; Akamatsu Y
J Immunol; 2021 Mar; 206(5):1102-1113. PubMed ID: 33495237
[TBL] [Abstract][Full Text] [Related]
15. B70/B7-2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells.
Caux C; Vanbervliet B; Massacrier C; Azuma M; Okumura K; Lanier LL; Banchereau J
J Exp Med; 1994 Nov; 180(5):1841-7. PubMed ID: 7525840
[TBL] [Abstract][Full Text] [Related]
16. Abatacept does not induce direct gene expression changes in antigen-presenting cells.
Carman JA; Davis PM; Yang WP; Zhu J; Chang H; He A; Truong A; Suchard SJ; Nadler SG
J Clin Immunol; 2009 Jul; 29(4):479-89. PubMed ID: 19259798
[TBL] [Abstract][Full Text] [Related]
17. Opposing effects of CTLA4-Ig and anti-CD80 (B7-1) plus anti-CD86 (B7-2) on experimental allergic encephalomyelitis.
Perrin PJ; Scott D; Davis TA; Gray GS; Doggett MJ; Abe R; June CH; Racke MK
J Neuroimmunol; 1996 Mar; 65(1):31-9. PubMed ID: 8642061
[TBL] [Abstract][Full Text] [Related]
18. Selective blockade of CD28 and not CTLA-4 with a single-chain Fv-alpha1-antitrypsin fusion antibody.
Vanhove B; Laflamme G; Coulon F; Mougin M; Vusio P; Haspot F; Tiollier J; Soulillou JP
Blood; 2003 Jul; 102(2):564-70. PubMed ID: 12649149
[TBL] [Abstract][Full Text] [Related]
19. B7-CTLA4 interaction enhances both production of antitumor cytotoxic T lymphocytes and resistance to tumor challenge.
Zheng P; Wu Y; Guo Y; Lee C; Liu Y
Proc Natl Acad Sci U S A; 1998 May; 95(11):6284-9. PubMed ID: 9600957
[TBL] [Abstract][Full Text] [Related]
20. Assessment of belatacept-mediated costimulation blockade through evaluation of CD80/86-receptor saturation.
Latek R; Fleener C; Lamian V; Kulbokas E; Davis PM; Suchard SJ; Curran M; Vincenti F; Townsend R
Transplantation; 2009 Mar; 87(6):926-33. PubMed ID: 19300198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
